(Reuters) – The U.S. health regulator said on Tuesday it would review guidance and rules about manufacturing infant formula as part of its strategy to prevent bacterial illness similar to Abbott Laboratories’ products this year. The Food and Drug Administration will also consider whether to establish a dedicated group... read full story